JPWO2022036137A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022036137A5 JPWO2022036137A5 JP2023509799A JP2023509799A JPWO2022036137A5 JP WO2022036137 A5 JPWO2022036137 A5 JP WO2022036137A5 JP 2023509799 A JP2023509799 A JP 2023509799A JP 2023509799 A JP2023509799 A JP 2023509799A JP WO2022036137 A5 JPWO2022036137 A5 JP WO2022036137A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- antigen
- concentration
- peptide antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065327P | 2020-08-13 | 2020-08-13 | |
| US63/065,327 | 2020-08-13 | ||
| PCT/US2021/045800 WO2022036137A1 (en) | 2020-08-13 | 2021-08-12 | T cell manufacturing compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539056A JP2023539056A (ja) | 2023-09-13 |
| JPWO2022036137A5 true JPWO2022036137A5 (https=) | 2024-08-21 |
| JP2023539056A5 JP2023539056A5 (https=) | 2024-08-21 |
Family
ID=80248187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509799A Pending JP2023539056A (ja) | 2020-08-13 | 2021-08-12 | Ｔ細胞を製造する組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230374455A1 (https=) |
| EP (1) | EP4196135A4 (https=) |
| JP (1) | JP2023539056A (https=) |
| KR (1) | KR20230074719A (https=) |
| CN (1) | CN116710551A (https=) |
| AU (1) | AU2021325081A1 (https=) |
| BR (1) | BR112023002733A2 (https=) |
| CA (1) | CA3189285A1 (https=) |
| CL (1) | CL2023000437A1 (https=) |
| CO (1) | CO2023002953A2 (https=) |
| CU (1) | CU20230011A7 (https=) |
| IL (1) | IL300564A (https=) |
| MX (1) | MX2023001815A (https=) |
| WO (1) | WO2022036137A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| CA3254900A1 (en) * | 2022-03-30 | 2023-10-05 | Mdx Management Llc | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS |
| CN121548636A (zh) * | 2023-06-19 | 2026-02-17 | 北京沙砾生物医药股份有限公司 | 一种肿瘤特异性细胞的富集方法和应用 |
| WO2025245492A1 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| AU4998993A (en) | 1992-08-07 | 1994-03-03 | Epimmune, Inc. | Hla binding peptides and their uses |
| CN1118572A (zh) | 1993-03-05 | 1996-03-13 | 萨依特尔有限公司 | Hla-a2.1组合肽及其用途 |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| EP3446119A1 (en) | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
| CA3081840A1 (en) * | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| WO2020047449A2 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
-
2021
- 2021-08-12 US US18/007,024 patent/US20230374455A1/en active Pending
- 2021-08-12 CA CA3189285A patent/CA3189285A1/en active Pending
- 2021-08-12 BR BR112023002733A patent/BR112023002733A2/pt unknown
- 2021-08-12 CN CN202180070338.2A patent/CN116710551A/zh active Pending
- 2021-08-12 KR KR1020237008593A patent/KR20230074719A/ko active Pending
- 2021-08-12 AU AU2021325081A patent/AU2021325081A1/en active Pending
- 2021-08-12 MX MX2023001815A patent/MX2023001815A/es unknown
- 2021-08-12 WO PCT/US2021/045800 patent/WO2022036137A1/en not_active Ceased
- 2021-08-12 JP JP2023509799A patent/JP2023539056A/ja active Pending
- 2021-08-12 EP EP21856741.0A patent/EP4196135A4/en active Pending
- 2021-08-12 CU CU2023000011A patent/CU20230011A7/es unknown
- 2021-08-12 IL IL300564A patent/IL300564A/en unknown
-
2023
- 2023-02-10 CL CL2023000437A patent/CL2023000437A1/es unknown
- 2023-03-10 CO CONC2023/0002953A patent/CO2023002953A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foy et al. | Non-viral precision T cell receptor replacement for personalized cell therapy | |
| Morotti et al. | Promises and challenges of adoptive T-cell therapies for solid tumours | |
| Ott et al. | A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer | |
| Bhardwaj et al. | Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets | |
| JP2024041873A5 (https=) | ||
| Monsurro et al. | Functional heterogeneity of vaccine-induced CD8+ T cells | |
| KR102946326B1 (ko) | T-세포 요법을 위한 신생항원 동정 | |
| Lu et al. | Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing | |
| Schrama et al. | Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue | |
| JP7034955B2 (ja) | 免疫療法向けのｔ細胞組成物 | |
| JP7668226B2 (ja) | Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用 | |
| Novak et al. | MHC class II tetramers identify peptide-specific human CD4+ T cells proliferating in response to influenza A antigen | |
| JP2024038503A5 (https=) | ||
| Kammula et al. | Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination | |
| Kast et al. | Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies | |
| JP2021073440A (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| BR112021003305A2 (pt) | métodos para produzir células que expressam receptor de antígeno quimérico | |
| Ali et al. | T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes | |
| Knutson et al. | IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion | |
| Connerotte et al. | Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities | |
| JP2025084864A (ja) | Ｔ細胞受容体の選択 | |
| Wölfl et al. | Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy | |
| Zhang et al. | A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3. DP4‐peptide‐pulsed dendritic cells | |
| Golden et al. | Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset | |
| Oh et al. | Characteristics of a CCL21 gene–modified dendritic cell vaccine utilized for a clinical trial in non–small cell lung cancer |